Universal Cells
Focus: Universal Cells is a public biotech company headquartered in Seattle specializing in non-immunogenic cell therapies. The company operates at an early commercial or pre-commercial stage with minimal disclosed pipeline activity.
Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
2+2 this month
Stable — net +2 jobs in 30d
2 added, 0 removed. Backfill posture.
Should You Work at Universal Cells?
AI assessmentUniversal Cells represents a speculative early-stage opportunity with differentiated science but significant visibility gaps on execution and financial stability.
Why Work Here
- Pioneering focus on non-immunogenic cell therapies addresses a significant unmet need in regenerative medicine and transplantation
- Seattle location offers access to strong biotech talent pool and innovation ecosystem
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Stable
Peak
Multiple oxygen-based formulations dominate the disclosed product list, suggesting either data quality issues or a non-core revenue stream.
Help build intelligence for Universal Cells
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.